Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study
Sign Up to like & getrecommendations! Published in 2022 at "Diabetes Care"
DOI: 10.2337/dc22-1514
Abstract: OBJECTIVE To determine whether the benefits of dapagliflozin in patients with type 2 diabetes and chronic kidney disease (CKD) in the Dapagliflozin And Prevention of Adverse Outcomes in CKD trial (DAPA-CKD) varied by background glucose-lowering… read more here.
Keywords: prespecified analysis; end point; dapa ckd; baseline ... See more keywords